This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
CLL Society Global Virtual Patient & Caregiver Educational Forum October 10!
The BIG event! CLL Society’s first-ever Virtual Global Patient Educational Forum. Register now! Can’t miss topics from CLL experts, including early management in CLL, Test Before Treat™, frontline therapy options, 2nd-line and later therapies, measuring response, MRD, COVID-19, clinical trials, CAR-T, vaccines, Richter’s Transformation, and more! Hear from patients and caregivers about how to become your own best advocate and learn the value of joining support groups.
The CLL Society 2020 Patient Survey: MRD Testing & Limited Duration Therapy
Your input + our future programming = Smarter Patients Getting Smarter Care! Make the CLL Society smarter! Help us find out what our CLL patients and their caregivers know and still “yearn to learn” about MRD testing (Minimal Residual Disease) and Limited Duration Therapies. Please complete our 2020 Patient Survey. Thank you!
When CLL Meets COVID-19
We are pleased to share with you the preeminent Spanish physician Prof. Dr. Emili Montserrat’s excellent commentary, recently published in BLOOD, reviewing two large studies on SARS-Cov2 infections in CLL patients. Prof. Dr. Emili Montserrat is one of the most prestigious and most cited leukemia and lymphoma specialists in the world. Please see Dr. Koffman’s summary (a commentary on a commentary!) which includes a link to the BLOOD article as well as links to the two important studies referenced.
The ECOG (E1912) Phase III, randomized, open label, clinical trial, comparing the efficacy of combination ibrutinib and rituximab with standard chemo-immunotherapy (FCR in patients 70 years of age or younger with previously untreated CLL) was a huge game-changer for CLL patients. We are happy to share with you Dr. Koffman’s ASH 2019 interview with Dr. Neil Kay showing that five-year data continue to yield evidence of the superiority of ibrutinib to chemoimmunotherapy for most CLL patients. To understand the powerful impact of this evidence on best practice and learn the subtleties, click here.
We are proud to bring you the news that CLL Society’s Bruce Wright, US Military Veteran and longtime member of the CLL Society Patient Advisory Board who was one of the original CLL Society Senior Support Group Advisors helping to establish and support several of our CLL-specific Support and Education groups across the country, has accepted an appointment to serve as the voice of veterans when relevant research issues are being addressed at the Southwest Oncology Group’s (SWOG) monthly meetings. Kudos to SWOG for giving patient advocates an equal voice at all meetings while planning their research. To learn more about Bruce’s appointment and SWOG’s integral place in research and clinical trials, please see Dr. Koffman’s write-up here.
Archived Webinar: Expert Perspectives on Incorporating BTK Inhibitors into the Treatment Plan for Patients with CLL
On September 3, US Military Veteran Bruce Wright joined Dr. Parameswaran Venugopal in a discussion of the clinical use of BTK inhibitors for the treatment of CLL, as well as how patients can best equip themselves with the appropriate knowledge to make informed decisions with their care providers, covering some of the challenges that are specific to veterans seeking treatment, as well as how patients and caregivers can increase their knowledge about CLL and become more involved in their treatment decisions. Watch the replay here.
Please Support the CLL Society, the only CLL-specific, physician-curated public charity dedicated to meeting the unmet needs of CLL patients and their caregivers which holds the GuideStar Platinum Seal of Transparency.
Thank you and stay safe!
We are all in this together.
Co-Founder & Communications Director
CLL Society Support Group Meetings Coming Up!
Visit the individual event listings on our website for the most up-to-date information on all CLL Society Support Group meetings.